Testing new drugs for high-risk bladder cancer after surgery
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new combination of drugs (Dato-DXd plus rilvegostomig) against standard treatments for people with high-risk, muscle-invasive bladder cancer that has been surgically removed. The goal is to see if the new treatment reduces the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have had surgery to remove your bladder cancer (or upper tract cancer) with clear edges, between 28 and 120 days ago.
- Your cancer is muscle-invasive (has grown into the muscle layer) and is at high risk of coming back, based on your surgical report.
- You have no signs of cancer on any scans at the time of screening.
- You are able to do most of your daily activities without help (ECOG score 0 or 1).
- You have a tissue sample from your surgery available for testing, and your organs are working well enough for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a combination of three drugs before bladder removal surgery in people with muscle-invasive bladder cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of a targeted drug (HDAC inhibitor, given directly into the bladder) and an immunotherapy (Durvalumab, given through a vein) before bladder removal surgery. It's for people with muscle-invasive bladder cancer who cannot take the chemo drug cisplatin.
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder removal surgery can improve outcomes for people with muscle-invasive bladder cancer. It aims to see if this combination is more effective than chemotherapy alone.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to see if they can control muscle-invasive bladder cancer without needing to remove the bladder. It may be an option for people who want to try to preserve their bladder and avoid surgery or radiation.
Hear when a new High-risk Muscle Invasive Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.